For medical information, general AI frontier models (Google, OpenAI, Anthropic) outperformed specialized @EvidenceOpen and @UpToDate as assessed by 12 US clinicians, randomized and blinded to which model and extensive testing/benchmarks. This was not anticipated. @NatureMedicinenature.com/articles/s41591-0…
I am thrilled to participate on behalf @utmbhealth on the @NatureMedicine Commission on Brain Health for Economic Resilience" which is a global, transdisciplinary team-effort to define, measure, and further brain health as well as cognitive capacity.
This will substantially support the foundational drivers of economic resilience.
More data supporting GFR cut off of 60 ml/min/1.732m2 and eGFRcr-cys linked with clinical outcomes
Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes | Reproductive Health | JAMA | JAMA Network #gfr#jamajamanetwork.com/journals/jam…
A very impressive study for how we could prevent lung cancer more than 5 years before it is diagnosed. Using machine learning, discovery of a 14-plasma protein signature of risk that predicts responsiveness to an antibody therapy to interleukin, IL-1β
Validated across 8 cohorts
@CellCellPress@CharlesSwantoncell.com/cell/fulltext/S0092…
👏 Congratulations to ASN President @samirparikhmd on his appointment as Chair of Internal Medicine at @UTSWInternalMed. This well-deserved achievement reflects his leadership and commitment to advancing clinical care, research, education, and kidney health.
🗣️The wait is over. The #KidneyWk 2026 program is here.
Explore 17 Learning Pathways featuring 140 educational sessions, 7 Early Programs, 600 expert faculty, 4,000 abstracts, and more. Registration and housing open Wednesday, June 24, at 10:00 a.m. EDT.
👉asn.kdny.info/1ZmN50Z5ESj
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM#ASCO26 | @ASCO
ALT A two-panel line graph shows overall survival in two populations, comparing darovasertib (blue line) and chemotherapy (gray line) treatments. Panel A depicts the RAS G12 population, while Panel B shows the overall population. Hazard ratios and confidence intervals are detailed in each panel.
ALT This image shows two line graphs titled "Progression-free Survival in the RAS G12 Population" and "Progression-free Survival in the Overall Population." Both graphs compare survival rates over 13 months between two groups: one receiving darovasertib and the other receiving chemotherapy. Accompanying the graphs are tables detailing the number of events and patients at risk for each treatment group.
Another major advance vs cancer! @ASCO#ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
ascopubs.org/doi/10.1200/JCO…
Curiosity rather than feeling stupid is the key to scientific advancement…stay humble and hungry
The Astounding Discovery That Could Link Eastern and Western Medicine nytimes.com/interactive/2026… via @NYTimes
We initially reported Semaphorin 3B (SEMA3B) as a target antigen in pediatric membranous nephropathy (MN)
However, we are also seeing SEMA3B in adult MN.
Unique features of adult SEMA3B MN: Most patients are middle aged adult females (86%), almost half had a history of pregnancy/miscarriage.
I wonder if the pediatric SEMA3B MN and adult female/pregnancy associated SEMA3B MN are somehow related.
kireports.org/article/S2468-…
Debate on a phenotype that is poorly measured and managed in clinical practice. 13 minutes to measure BP is not a practical recommendation. #hypertension@NEJM Blood-Pressure Targets in Hypertension Management | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
Three years ago today, Dawn Bulgarella and I were appointed by the UA System Board of Trustees. Grateful to serve alongside Dawn and honored to help advance the @uabmedicine and @UABHeersink shared mission and vision - looking forward to the work ahead.
We are thrilled to announce that Dr. Anupam Agarwal has been named dean of the UAB Marnix E. Heersink School of Medicine, senior vice president of Medicine and chair of the Health Services Foundation Board.
Learn More: go.uab.edu/3l6dMEH@anupamuab@UABNews@uabmedicine
🎉Congratulations to @samirparikhmd, who begins the 2026 term as President of the American Society of Nephrology. Dr. Parikh will lead key initiatives and guide important work across the kidney care community.
Learn about Dr. Parikh: asn.kdny.info/iNXu50XKBn8